# Chipscreen Biosciences, Ltd.

Organization · id `cardio:org-chipscreen-biosciences-ltd` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Chipscreen+Biosciences%2C+Ltd.>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 4 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Chipscreen Biosciences, Ltd.
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients (`cardio:ct-nct02121717`)
- Sponsors: Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients (`cardio:ct-nct02173457`)
- Sponsors: Chiglitazar Added to Metformin for Type 2 Diabetes (`cardio:ct-nct04807348`)
- Sponsors: A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus (`cardio:ct-nct07303803`)

## Provenance

Content hash: eaf2cfb28319e6982145e0b2e71c541ba229a487a0428e71307b4b5fdf5db247
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
